Radiation therapy clinical trials for dogs and cats

Lattice or SBRT radiotherapy for large inoperable canine tumors

University of Zurich — Division of Radiation Oncology · Switzerland

Ongoing European oncology clinical trial — listed by Oncowaf

What is being offered: Randomized therapeutic comparison of Lattice radiotherapy and SBRT for large inoperable canine tumors, or when radiotherapy is preferred to surgery. Five consecutive daily treatment sessions. Research biopsies are requested when safely accessible; the treating team confirms final eligibility and consent. Single enrolling center: University of Zurich Veterinary Hospital.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Large inoperable or rt preferred

Costs / coverage: 🟠 Partially funded. Owners pay the initial consultation, radiation-planning CT and anesthesia for the radiation treatments. Research funding covers the radiation itself and CT or MRI follow-up examinations at six and twelve months.

Contact: University of Zurich Radiation Oncology — +41 44 635 81 12

Official study / enrollment information →

Palliative radiation + frunevetmab for feline bone-invasive oral SCC

University of Pennsylvania · USA

Active - Recruiting

What is being offered: Pilot palliative study for feline bone-invasive oral SCC.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; No metastasis; Mandibular or maxillary bone lysis; chemotherapy washout: 21 days; radiation washout: 21 days; Immunotherapy and anti ngf washout 21d

Costs / coverage: 🟠 Partially funded. Owners pay initial staging to establish eligibility, including the initial head CT, bloodwork and diagnostic cytology/histopathology of the oral mass and lymph nodes when needed. After enrollment, the study covers all six radiation treatments including anesthesia and examinations, Solensia/placebo and meloxicam, monitoring bloodwork, chest radiographs and the final head CT.

Contact: Penn Vet VCIC — vcic@vet.upenn.edu; 215-573-0302

Official study / enrollment information →

Half-body radiotherapy plus CHOP for canine multicentric lymphoma

University of Wisconsin–Madison School of Veterinary Medicine · USA

Recruiting — new UW cohort posted September 1, 2026

What is being offered: 25-week CHOP chemotherapy with four high-dose-rate half-body radiation fractions: two cranial fractions in week 11 and two caudal fractions in week 15

Who may qualify: Confirmed cancer diagnosis required; Lymphoma response: Partial response; Complete remission; Prior chemo; Planned radiation; Planned doxorubicin; Current chop; Large cell multicentric stage iii or higher; Two chop cycles completed

Costs / coverage: Study covers radiation, radiation anesthesia, associated boarding if needed, two CBCs, two chemistry panels and two urinalyses. Owners pay CHOP chemotherapy, routine follow-up, additional testing, adverse-event treatment and other costs not specifically covered.

Contact: UW Radiation Oncology — radonc@vetmed.wisc.edu · 608-263-7600; Dr. Michelle Turek / Dr. Rey Chi

Official study / enrollment information →

Randomized FLASH versus conventional radiotherapy for canine appendicular osteosarcoma

University of Wisconsin–Madison School of Veterinary Medicine · USA

Recruiting — listed on the current UW Veterinary Care oncology studies page

What is being offered: One randomized FLASH or conventional-dose-rate radiation treatment, weekly follow-ups, and amputation at approximately one month under the current study consent

Who may qualify: Active tumor required; Appendicular location; Planned amputation; Planned radiation

Costs / coverage: Study covers radiation therapy and amputation scheduled one month after study start. Medications prescribed for study-related side effects are not covered. Confirm screening and other owner-paid costs with the study team.

Contact: Dr. Tricia Hu — tghu@wisc.edu; Dr. Nathaniel Van Asselt — nvanasselt@wisc.edu; UW Oncology Service — 608-890-0422

Official study / enrollment information →

AI-guided biomechanical modeling and minimally invasive stabilization with SBRT for appendicular osteosarcoma

Ohio State University · USA

Current enrolling clinical trial — July 2026 list

What is being offered: Appendicular OSA treated with stereotactic body radiation; patient-specific biomechanical modeling identifies dogs who may benefit from intramedullary stabilization.

Who may qualify: No metastasis; Active tumor required; Appendicular location; Planned radiation; Planned chemo

Costs / coverage: 🟡 Partially funded. Study covers pre-operative limb CT and gait assessment, implant placement/anesthesia, implant, fluoroscopy, histopathology, specified limb radiographs and gait follow-up. A $1,000 direct payment is provided after study completion. SBRT and carboplatin chemotherapy are not covered.

Contact: Ohio State Blue Buffalo Veterinary Clinical Trials Office — CVM-ClinicalTrials@osu.edu

Official study / enrollment information →

Radiation plus intratumoral IL-12 immunotherapy for canine osteosarcoma

University of Illinois · USA

Current funded oncology clinical trial

What is being offered: Radiation to the affected limb followed by intratumoral JEN-101 at day 2 and week 2, then amputation at week 4

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Planned radiation; Planned amputation

May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Prior steroids; Immunosuppressive

Costs / coverage: Partially funded after eligibility: radiation, JEN-101 and associated treatment-visit charges; follow-up abdominal ultrasound and chest radiographs; and up to $2,500 toward amputation at Illinois are covered. Owner pays screening, recheck exams/bloodwork and remaining amputation cost.

Contact: Rebecca Kamerer, Clinical Trials Coordinator — rmoss81@illinois.edu · 217-300-6453; appointments 217-333-5300

Official study / enrollment information →

Whole-abdomen radiation followed by COP/doxorubicin for feline high-grade gastrointestinal lymphoma

University of Missouri Veterinary Health Center · USA

Currently enrolling — University of Missouri Veterinary Health Center

What is being offered: Whole-abdomen radiation therapy followed by COP/doxorubicin chemotherapy

Who may qualify: Confirmed cancer diagnosis required; Planned radiation; Planned chemo; High grade abdominal gi lymphoma; Felv fiv negative

May not qualify if: Prior chemo; Current chemo; Small cell lymphoma; Severe systemic disease

Costs / coverage: Partially funded. The study covers whole-abdomen radiation and provides a $1,000 credit for care at the VHC after radiation is completed. Published information does not specify screening, COP/doxorubicin chemotherapy, other care or travel coverage; confirm these costs with the study team.

Contact: Oncology Clinical Trials — cvmclinicaltrials@missouri.edu; VHC 573-882-7821

Official study / enrollment information →

Radiation therapy plus XCSgel immunotherapy for canine soft tissue sarcoma

NC State College of Veterinary Medicine · USA

Actively recruiting — enrollment finish August 31, 2027

What is being offered: Blinded study of standard radiation therapy plus XCSgel immunotherapy; all enrolled dogs receive surgery and radiation, while XCSgel versus placebo is blinded. Pathologic confirmation of STS required and no prior radiation or chemotherapy.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Min tumor cm: 4; Max tumor cm: 10; Planned surgery; Planned radiation

May not qualify if: Prior chemo; Prior local radiation

Costs / coverage: 🟢 Fully funded — NC State states enrolled dogs receive free testing, treatment and follow-up, including bloodwork, CT, surgery and radiation therapy.

Contact: NC State Clinical Studies Core — see official trial page

Official study / enrollment information →

Lapatinib plus fractionated radiation therapy for canine transitional cell carcinoma

Colorado State University Flint Animal Cancer Center · USA

Actively recruiting — listed on CSU current clinical trials page

What is being offered: Daily oral lapatinib plus NSAID and 15 radiation fractions, with monthly follow-up for three months. Source timetable says 15 daily treatments within seven days of starting pills; this inconsistency requires study-team clarification rather than a guessed schedule.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation; radiation washout: 42 days; chemotherapy washout: 14 days; Nsaid tolerant

Costs / coverage: 🟡 Partially funded. Lapatinib, recheck examinations, study bloodwork, urinary ultrasounds/sedation and $3,000 toward discounted radiation are covered; some side-effect funding is available. Owners pay initial examination/diagnosis including cystoscopy/biopsy, NSAID medication and radiation costs beyond study support.

Contact: CSU Flint Animal Cancer Center Clinical Trials — (970) 297-4001; online clinical-trial consult form

Official study / enrollment information →

Proton FLASH radiation therapy for canine extremity soft tissue sarcoma

University of Pennsylvania School of Veterinary Medicine · USA

Current Penn Vet clinical trial

What is being offered: Three proton FLASH-RT treatments over 5–9 days for extremity STS where surgery is not feasible or has been declined. Prior surgery is acceptable.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Extremity sts; Max tumor cm: 10; No metastasis; Planned radiation

May not qualify if: Pulmonary metastasis; Regional lymph node metastasis

Costs / coverage: 🟢 Fully funded after screening. Sponsor covers all study-related procedures including FLASH-RT treatments, examinations, chest radiographs, laboratory tests, sedation/anesthesia and CT; the screening visit is owner-paid.

Contact: Penn Vet VCIC — 215-573-0302; vcic@vet.upenn.edu

Official study / enrollment information →

CAR-Neutrophils Combined with Radiation for Canine Glioma

UT Southwestern Veterinary Research and Oncology Clinic · USA

Actively recruiting — confirmed on UT Southwestern VROC current trials page

What is being offered: CAR-neutrophils plus radiation therapy

Who may qualify: Active tumor required; Planned radiation; Prednisone eligible; Anticancer treatment washout

May not qualify if: Prior local radiation; Severe systemic disease; Nonstop antioxidant supplements

Costs / coverage: 🟢 Study-subsidized. The protocol brochure states that owners pay only for diagnostics, imaging, palliative care and other tests or care needed outside the study.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Ferumoxytol Combined with Radiation for Canine Glioma

UT Southwestern Veterinary Research and Oncology Clinic · USA

Actively recruiting — confirmed on UT Southwestern VROC current trials page

What is being offered: Ferumoxytol plus radiation therapy

Who may qualify: Active tumor required; Planned radiation; Prednisone eligible; Anticancer treatment washout

May not qualify if: Prior local radiation; Severe systemic disease; Nonstop antioxidant supplements

Costs / coverage: 🟡 Funding varies. The protocol brochure states that the study may be fully or partially subsidized; owners may pay for diagnostics, imaging, palliative care and other tests or care needed outside the study.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Chemoradiation for canine high-grade glioma

University of Zurich Veterinary Hospital · Switzerland

Participation currently possible on the University of Zurich study page

What is being offered: All enrolled dogs receive radiotherapy. Dogs are randomized to temozolomide plus lomustine or placebo to evaluate added chemotherapy for high-grade glioma.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation

Costs / coverage: The university states that biopsy, chemotherapy and study laboratory tests are covered and radiotherapy is discounted; confirm all costs directly.

Contact: University of Zurich Radiation Oncology — +41 44 635 81 12

Official study / enrollment information →

FLASH proton radiotherapy for feline oral squamous cell carcinoma

University of Zurich Veterinary Hospital · Switzerland

Participation currently possible on the University of Zurich study page

What is being offered: Current randomized study comparing FLASH and conventional proton radiotherapy for cats with oral squamous cell carcinoma, including tongue tumors. Radiation is given on three consecutive days at the Paul Scherrer Institute; cats remain hospitalized for four days at the University of Zurich Veterinary Hospital. Zurich handles enrollment and inpatient veterinary care; PSI is the radiation-delivery partner, not a separate owner-enrollment clinic. Initial CT and biopsy establish tumor extent/type; a temporary feeding tube is placed for treatment. Clinical follow-ups are weekly in month1 and every three months in year1, with CT at6,12,18 months. Final eligibility is confirmed by the study team.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation

Costs / coverage: 🟠 Partially funded. Owners pay half the initial diagnostic work-up cost: imaging, biopsy and blood tests. The official study flyer states that no further costs arise from the time of study enrollment. Confirm the current estimate and any unrelated care with the Zurich study team.

Contact: University of Zurich study team — Dr. Maximilian Körner; +41 44 635 95 55; onkologie@vetclinics.uzh.ch

Official study / enrollment information →

FLASH radiotherapy for canine superficial malignant tumors

University Hospital for Companion Animals, University of Copenhagen / Lund University · Denmark

Recruiting/current project — University of Copenhagen lists patients for the 2020–2027 FLASH radiotherapy project

What is being offered: Dogs with a cancer mass in skin, subcutis or oral cavity, including incompletely removed/residual tumor, may participate when there is expected therapeutic benefit. Dogs receive 1–4 radiotherapy treatments over up to four weeks; most receive FLASH and a smaller group conventional radiotherapy. Treatment requires travel within the Copenhagen/Lund collaboration.

Who may qualify: Active tumor required; Superficial or oral tumor; Anesthesia fit; Planned radiation

Costs / coverage: The project states that treatment and follow-up visits are paid by the project; owner is responsible for EU pet passport/rabies requirements for travel to Sweden.

Contact: Betina Børresen — bb@sund.ku.dk

Official study / enrollment information →

CARE trial: autophagy inhibition plus radiation for canine glioma

UC Davis Weill School of Veterinary Medicine / Translational Brain Tumor Center · USA

Actively recruiting — UC Davis recruitment announcement published September 3, 2026

What is being offered: Investigational autophagy inhibitor bisaminoquinoline-13 (BAQ-13), given intravenously twice weekly for four weeks with conventional radiation therapy and paired brain-tumor biopsies

Who may qualify: Active tumor required; Suspected or confirmed glioma; Radiation therapy; Brain tumor biopsy; Planned radiation

Costs / coverage: Study covers study-related MRI/CT scans except the initial diagnostic MRI, brain-tumor biopsies, BAQ-13 and monitoring, and hospitalization related to study procedures. It provides $4,000 toward radiation costs at completion of RT and BAQ-13 treatment. Owners pay initial eligibility diagnostics and radiation costs beyond the contribution. Study-related complication care at UC Davis VMTH is covered up to $3,000.

Contact: UC Davis Veterinary Center for Clinical Trials — (530) 754-1954; contact Dr. Christine Toedebusch / study team via the official UC Davis page

Official study / enrollment information →

Radiation therapy plus temozolomide for canine brain tumors

Johns Hopkins Center for Image-Guided Animal Therapy (CIGAT) · USA

Open and enrolling — current Johns Hopkins CIGAT clinical-trials page

What is being offered: Treatment study for dogs with a suspected glioma/intra-axial brain tumor greater than 1 cm on MRI and restricted to one side of the brain. Protocol uses five consecutive workdays of radiation therapy with concurrent oral temozolomide. Previous or current oncologic treatment of the brain tumor is exclusionary; investigator prescreening is required.

Who may qualify: Active tumor required; Min age years: 1; Min weight kg: 10; Brain tumor present; Planned radiation; Planned chemo

May not qualify if: Prior local radiation; Prior chemo

Costs / coverage: 🟢 Fully funded protocol treatment. Radiation therapy and chemotherapy are fully funded, and study-related side-effect medications, follow-up MRI and blood tests are covered; treatment after progression is not covered.

Contact: Johns Hopkins CIGAT — 410-502-7325; contact through the official clinical-trials page

Official study / enrollment information →

Radiation with or without intra-arterial chemotherapy for canine nasal cancer

UC Davis Veterinary Medical Teaching Hospital · USA

Active - Recruiting

What is being offered: Radiation therapy alone or combined with intra-arterial chemotherapy

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Radiation therapy; Planned radiation

Costs / coverage: 🟡 Partially funded. The study pays for CT scans, chemotherapy administration and part of radiation therapy.

Contact: Dr. Bill Culp — wculp@ucdavis.edu; 530-752-1393

Official study / enrollment information →

Whole-abdomen radiation therapy for relapsed feline small-cell gastrointestinal lymphoma

Texas A&M School of Veterinary Medicine · USA

Actively recruiting — Texas A&M oncology

What is being offered: Current investigator-linked primary protocol: biopsy-confirmed feline small-cell gastrointestinal lymphoma, either newly diagnosed but difficult to medicate or relapsed after chemotherapy. Cats need pretreatment blood/urine testing within 14 days and at least seven days without chemotherapy or corticosteroids before radiation. Owners must live within a six-hour drive of College Station. Whole-abdomen radiation under anesthesia on days 0-4, then visits at two and six weeks; owner stool samples and quality-of-life surveys through up to 18 months. Study-related costs after enrollment are covered; screening panels and possible overnight hospital housing remain owner costs.

Who may qualify: Confirmed cancer diagnosis required; Planned radiation; chemotherapy washout: 7 days; steroid washout days: 7 days; Small cell gastrointestinal lymphoma; Within six hours of college station

Costs / coverage: 🟡 Study-related costs are covered after enrollment. Owners pay screening blood/urine panels within 14 days before enrollment; overnight hospital housing may incur an additional charge.

Contact: Regina Hayburn, DVM, DACVIM (Oncology) — rhayburn@tamu.edu

Official study / enrollment information →

Single-fraction radiation therapy for canine transmissible venereal tumor

Colorado State University Veterinary Teaching Hospital · USA

Active - Recruiting

What is being offered: CSU protocol IACUC 7968 evaluates one modern radiation treatment for dogs with a confirmed, measurable and sampleable TVT lesion larger than 1 cm. Dogs must be suitable for anesthesia, have no advanced spread and have received no prior surgery, radiation or systemic chemotherapy for the tumor. Immunosuppressive drugs require a seven-day washout. Rechecks occur on Days 7 and 28.

Who may qualify: Confirmed cancer diagnosis required; Measurable; Active tumor required; Planned radiation; Min tumor cm exclusive: 1; Immunosuppressant washout 7d

May not qualify if: Prior surgery; Prior radiation; Prior systemic chemotherapy; Advanced metastatic disease

Costs / coverage: 🟡 Partially funded. The study covers pretreatment CBC/chemistry, indicated abdominal imaging, radiation planning and the single radiation treatment, plus Day 7 and Day 28 rechecks. If the tumor persists or progresses, a $1,000 credit is available toward standard chemotherapy.

Contact: CSU Oncology Clinical Trials — csuoncologytrials@colostate.edu; 970-297-4001

Official study / enrollment information →

FLASH proton radiation with or without gilvetmab for canine glioma

Penn Vet Ryan Veterinary Hospital · USA

Recruiting

What is being offered: Dogs need histopathologic confirmation of glioma or diagnostic MRI showing a supratentorial lesion consistent with glioma, must be suitable for general anesthesia, and must have a tumor compatible with the FLASH equipment. Systemic chemotherapy or immunotherapy requires a three-week washout; prior gilvetmab is not allowed. All dogs receive three FLASH proton treatments and are randomized to receive or not receive three gilvetmab infusions, with 12 follow-up visits over 11 months.

Who may qualify: Active tumor required; Planned radiation

May not qualify if: Prior gilvetmab; Anesthesia contraindicated

Costs / coverage: 🟡 Partially funded. Owners pay screening diagnostics; after enrollment the sponsor covers three FLASH-RT treatments, examinations, laboratory tests, sedation/anesthesia, CSF taps, gilvetmab infusions and protocol CT/MRI imaging.

Contact: Penn Vet VCIC — 215-573-0302; vcic@vet.upenn.edu

Official study / enrollment information →

Radiotherapy plus Lavurchin (SQAP) radiosensitizer for feline oral squamous cell carcinoma

Animal Medical Center, Gifu University · Japan

Recruiting on the official oncology clinical-trial index and individual protocol page

What is being offered: Five-day radiotherapy course with Lavurchin (SQAP) radiosensitizer, followed by visits at months 1, 3 and 6

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation

Costs / coverage: Lavurchin (SQAP) study-drug costs are covered. Ordinary treatment costs, including radiotherapy, remain owner-paid; confirm the full estimate with the center.

Contact: Gifu University oncology — 058-293-2962; vethsptl@t.gifu-u.ac.jp

Official study / enrollment information →

SBRT for canine primary pulmonary carcinoma

Tufts University Cummings School of Veterinary Medicine · USA

Recruiting — official Tufts individual protocol

What is being offered: A single cytologically or histopathologically confirmed primary pulmonary carcinoma must measure more than 1 cm in its shortest diameter and have received no previous tumor treatment. Multiple pulmonary nodules consistent with metastasis, regional node metastasis and pulmonary carcinomatosis exclude. No other malignant tumor diagnosed outside the lung within 30 days; a prior non-carcinoma malignancy can be allowed in remission if expected median survival exceeds one year. Screening CBC, chemistry and abdominal ultrasound within 30 days; anesthesia and SBRT suitability require clinician assessment. This is a VRTOG multicenter protocol, but the page does not name the other participating institutions; only the verified Tufts enrollment site is listed. Distinct from the Tufts SABR trial for progressive lung metastases.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Planned radiation; Min tumor cm exclusive: 1; Single primary pulmonary carcinoma

May not qualify if: Prior radiation; Regional lymph node metastasis; Pulmonary metastasis; Significant comorbidity; Prior target tumor treatment

Costs / coverage: Partially funded: up to $4,000 for anesthesia, radiation planning and SBRT; up to $1,000 may be available for follow-up chest radiographs. Owners pay pre-enrollment bloodwork, planning CT, diagnosis confirmation and hospitalization for complications.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu

Official study / enrollment information →

SBRT plus dendritic-cell homing hydrogel for canine appendicular osteosarcoma

University of Illinois Veterinary Teaching Hospital · USA

Currently listed as a funded clinical trial on the Illinois master roster

What is being offered: Three consecutive days of SBRT followed by local dendritic-cell homing hydrogel; weekly follow-up for five weeks

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Appendicular location; No metastasis; Min age years exclusive: 1; Min weight kg: 5; Planned radiation; Anesthesia candidate; steroid washout days: 14 days

May not qualify if: Prior chemo; Prior local radiation; Prior immunotherapy; Current steroids; Immunosuppressive

Costs / coverage: Fully funded after eligibility: CT, biopsy, three-day SBRT, hydrogel injection, study recheck exams and bloodwork. Owners pay the initial consultation (approximately $250), eligibility diagnostics, pain medication and unrelated care.

Contact: Rebecca Kamerer, Clinical Trials Coordinator — rmoss81@illinois.edu; 217-300-6453. Appointments: 217-333-5300.

Official study / enrollment information →